VEGFA and retinopathy of prematurity: ROP deemed high risk for disease progression that could result in a poor visual or anatomic outcome (Type 1 ROP) is treated with laser photocoagulation and/or intravitreal anti-VEGF antibody (bevacizumab) [6].